For some patients with kidney failure, the right care is not dialysis. Conservative kidney management — active, planned care of the failing kidney without dialysis — is a legitimate and often wise choice, particularly for the frail and the multi-morbid, and it is the chapter the timing and frailty chapters have been pointing toward. The single most important idea is that it is treatment, not its absence: a patient who chooses conservative management is choosing a different active path, not being abandoned.
What conservative management is — and is not
Conservative kidney management is active, holistic management of kidney failure without dialysis. It includes controlling symptoms, treating reversible contributors, managing the complications of kidney failure conservatively, preserving function and wellbeing where that helps, supporting the patient and family psychologically and spiritually, planning ahead, and integrating palliative care. It is emphatically not 'doing nothing,' not the withdrawal of care, and not, in itself, end-of-life care — though it may transition into comfort-only care as the patient approaches death. Holding this definition clearly matters because the commonest harm in this area is the framing: a patient told there is 'nothing more we can do' if they decline dialysis has been failed, when in fact a busy, attentive programme of conservative care is available. Conservative management is a treatment offered, not a door closed.
Who chooses it, and why
The patient for whom conservative management may serve best is, often, the frail, multi-morbid, elderly person whose kidney failure sits within a larger decline and who values quality and place of life over the extension dialysis might offer. The evidence, drawn from the frailty and capstone discussions, supports the choice: in the frail elderly, conservative management delivers a quality of life comparable to dialysis and, in the very frail, a similar survival, with fewer hospital days and a death more often in the preferred place. Dialysis in this group can add little time while exacting a heavy toll of access, sessions, and dislocation. None of this makes conservative management the right choice for everyone — a fitter patient may gain real time from dialysis — but it makes it a genuine, evidence-supported option that turns on the patient's values, and the choice between the two is therefore preference-sensitive, made through shared decision-making informed by an honest prognosis.
Controlling the symptoms of kidney failure
Choosing conservative management commits the team to active symptom control, because the symptoms of kidney failure are real and treatable. Uraemia brings nausea and anorexia, treated with antiemetics; pruritus, eased with emollients and, where needed, gabapentinoids dose-adjusted for kidney function; restless legs; and a heavy fatigue and insomnia, each addressed in turn. Fluid overload is managed with diuretics — often high-dose loop diuretics while they still work — alongside fluid and salt restriction, and breathlessness is treated. Anaemia is treated, with iron and an erythropoiesis-stimulating agent, for the symptomatic and quality-of-life benefit rather than chased to a target, at the moderate haemoglobin the anaemia chapter set out. As the patient declines, dietary restrictions are liberalised in favour of comfort and enjoyment. Conservative management done well is, in short, a great deal of attentive medicine — the opposite of neglect.
Pain, and the morphine trap
Pain in kidney failure deserves its own emphasis because the obvious drug is the wrong one. The analgesic ladder is adapted for the failing kidney: paracetamol is the safe foundation, NSAIDs are avoided for their nephrotoxicity, and — crucially — morphine is avoided because its active metabolites accumulate in kidney failure and cause toxicity, as the poisoning chapter of the previous volume described. The renally safer opioids — fentanyl, buprenorphine, alfentanil — are preferred, with oxycodone used cautiously, all dosed carefully for the reduced clearance. This is one of the most consequential prescribing points in conservative care: a patient managed conservatively will often need good analgesia, and reaching reflexively for morphine causes the very toxicity the choice of conservative care was meant to spare them. Renally safe analgesia is part of doing conservative management properly.
The pathway: palliative care, planning, and the dying phase
Conservative management is delivered as a coordinated pathway, not a single decision, and palliative care is a partner from the outset rather than a service summoned only at the very end. The team is multidisciplinary — nephrology, palliative care, primary and community care — and the work includes advance care planning, decisions about the place of care and death, and honest prognostication, for which the surprise question is a useful prompt. The path is reviewed over time, and the decision can be revisited, because some patients change their minds. And a specific clinical skill is recognising the dying phase — the point at which the patient is entering the last days of life — because that recognition prompts a shift from active conservative management to comfort-focused, end-of-life care, with its own priorities of symptom relief and dignity. Conservative management and comfort care are not the same, but the first flows into the second, and managing that transition well is central to the patient's experience of dying.
Effective care, and the decisions that are the patient's
As in every equipoise chapter, it helps to separate what is owed from what is chosen. Symptom control, honest prognostication, psychosocial and spiritual support, treating reversible factors, and never abandoning the patient are effective care, delivered to every patient on this path regardless of preference. The preference-sensitive decisions — conservative management versus dialysis in the first place, the place of care and death, how much intervention the patient wants, whether to attempt a time-limited trial of dialysis, and when to shift from active management to comfort-only — belong to the patient, made through the shared decision-making the chapter's scripts support. Keeping the two clear protects against the two opposite failures: drifting from appropriate conservative care into neglect, and overriding a patient's values with default intervention.
Where the evidence is firm, and where values govern
The firm parts are the supportive-care and outcome ones: that conservative management is active care, that morphine is dangerous in kidney failure while renally safer opioids are not, and that in the frail elderly conservative management can match dialysis on quality of life and, in the very frail, survival — the last from consistent observational data, since randomising this choice is rarely feasible. What evidence cannot settle is whether a given patient should choose conservative management or dialysis, or where and how they wish to be cared for, because those turn on values the trials do not measure. So the clinician's role is to deliver the active care expertly, to prescribe safely, to prognosticate honestly, and to share the values-laden choices — closing the preparation arc not on a machine but on the person, cared for actively in the way they have chosen.
